HURA (TuHURA Biosciences) Stock Based Compensation : $0.71 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Stock Based Compensation?

TuHURA Biosciences's Stock Based Compensation for the three months ended in Dec. 2024 was $0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was $0.71 Mil.

TuHURA Biosciences Stock Based Compensation Historical Data

The historical data trend for TuHURA Biosciences's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Stock Based Compensation Chart

TuHURA Biosciences Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Stock Based Compensation

0.66

0.22

0.48

1.96

TuHURA Biosciences Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Dec23	Mar24	Jun24	Sep24	Dec24
Stock Based Compensation	Get a 7-Day Free Trial				-	0.34	0.28	0.10	-

TuHURA Biosciences Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.71 Mil.

TuHURA Biosciences Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

N/A

Address

10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612

Website

https://www.tuhurabio.com

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.